nivolumab
bms
['melanoma', 'opdivo', 'nivo', 'nivolumab', 'check,mate,76k', 'bristol']
bristol myers squibb presents data from checkmate -76k showing opdivo (nivolumab) reduced the risk of recurrence or death by 58% versus placebo in patients with completely resected stage iib or iic melanoma 
Pharmaceutical News - Direct Information